| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
|
|
01-26-2012, 01:09 PM
|
#1 | |||
|
||||
|
Senior Member
|
http://www.brainstorm-cell.com/Index...ryID=76&Page=1
"...The NurOwn™ technology processes autologous adult human mesenchymal stem cells that are present in bone marrow and are capable of self-renewal as well as differentiation into many other cell types. Adult human bone marrow cells are induced to differentiate into astrocyte-like cells capable of releasing neurotrophic factors, including glial-derived neurotrophic factor (GDNF) by means of a specific differentiation-inducing culture medium. The ability to induce differentiation into astrocyte-like cells along with intramuscular or intrathecal (or other) delivery makes NurOwn™ technology highly attractive for treating ALS and Parkinson’s disease as well as MS and spinal cord injury..."
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| BrainStorm Announces Clinical Data Supporting Safety and Efficacy of NurOwn™... (ALS) | Parkinson's Disease | |||
| EASED™ (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dys | Parkinson's Disease | |||
| IPX066 Demonstrates Efficacy and Safety in ADVANCE-PD Phase III Study in Treatment of | Parkinson's Disease | |||
| Study to Investigate the Safety and Efficacy of Lithium in Volunteers With ALS | ALS News & Research | |||
Safety and Efficacy of NurOwn™ Based on Initial Patient Results
Hybrid Mode
